Skip to main content
. 2014 Feb 7;289(14):9795–9810. doi: 10.1074/jbc.M113.527150

FIGURE 10.

FIGURE 10.

FGF-23 injections. A, serum FGF-23 concentrations measured by ELISA pre- and postintraperitoneal injections of recombinant human FGF-23 in WT mice. Vehicle-treated mice were injected with PBS (n = 6 per group). B, Epo concentrations measured by ELISA in serum of WT mice injected with FGF-23 (5 μg) or vehicle (PBS). Samples were measured in duplicate. C–M, flow cytometry analysis and colony-forming assays of hematopoietic populations in FGF-23- and vehicle-treated WT mice. C–E, peripheral blood. C, percentage of early erythroid cells (pro-E) stained positive for Ter119med and CD71high. D, percentage of mature erythroid cells stained positive for Ter119. E, percentage of HSC population stained for LSK (Lin−Sca-1+c-Kit+). F–H, bone marrow. F, percentage of early erythroid cells (pro-E) stained positive for Ter119 and CD71high. G, percentage of mature erythroid cells stained positive for Ter119. H, representative dot plot of flow cytometry analysis of WT and Fgf-23−/− pro-E and Ter119+ cell populations in BM. I, colony forming assay for erythroid (BFU-E) progenitors. Cells from each mouse were plated in triplicate, and the number of colonies in each plate was counted. (n = 6 per group). J, percentage of HSC population stained for SLAM (CD150+CD48−). K–M, spleen. K, percentage of early erythroid cells (pro-E) stained positive for Ter119med and CD71high. L, percentage of mature erythroid cells stained positive for Ter119. M, percentage of HSC population stained for KTLS (Lin−Sca-1+c-Kit+Thy-1+). The data are represented as means ± S.E. *, p < 0.05.

HHS Vulnerability Disclosure